Genelux Corporation Announces New Chief Financial Officer
August 28, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the...
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
August 24, 2023 11:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Ovarian Cancer Market to Grow Rapidly at a CAGR of 16% by 2030 | DataM Intelligence
August 04, 2023 11:00 ET
|
DataM Intelligence
New York, Aug. 04, 2023 (GLOBE NEWSWIRE) -- The Global Ovarian Cancer Market is estimated to grow at a CAGR of 16% during the forecast period (2023-2030). Ovarian cancer is a significant public...
IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023
August 03, 2023 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
Gemcitabine HCL Market to Achieve CAGR of 7.4%, Exceeding US$ 1.3 Bn by 2031
July 26, 2023 09:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, July 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The gemcitabine HCL market was valued at US$ 635.1 Mn in 2021 and is projected to exceed...
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
July 20, 2023 11:45 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that the...
Oncology Biomarkers Global Market to 2028: Increased Availability and Ease of Biomarker Testing Fuels the Sector
July 04, 2023 05:13 ET
|
Research and Markets
Dublin, July 04, 2023 (GLOBE NEWSWIRE) -- The "Oncology Biomarkers: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global oncology biomarkers market reached a...
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
June 22, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the...
Genelux Corporation Announces $18 Million Private Placement
June 12, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares...
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
May 24, 2023 16:05 ET
|
Myriad Genetics, Inc.
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a...